Japan
Fermelanta, Inc. is a promising biotech startup, founded in October 2022, headquartered in Japan. The company employs innovative synthetic biology to create plant-based chemicals using microorganisms. By shifting away from conventional agriculture and extraction processes, they leverage microbial fermentation to deliver low-cost and high-quality products with improved efficiency.
Their proprietary technology focuses on the introduction and expression of unique foreign genes within cell factories, enabling microorganisms to produce critical extrinsic metabolites, which hold potential applications in health food, cosmetics, and approved drugs. Fermelanta is currently in a lab-based R&D stage and is actively seeking initial funding through its first-financing seed round.
To date, they have secured a $1.40M Seed Round investment, backed by notable investors including Beyond Next Ventures, Angel Bridge, and Plug and Play. The company's strategic focus on transforming the biotechnological landscape highlights its potential for growth and disruption within the Life Sciences sector.
